New drug SPG302 tested for schizophrenia in small trial

NCT ID NCT06442462

Ongoing Symptom relief Sponsor: Spinogenix Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests whether SPG302, a small synthetic molecule, can safely reduce schizophrenia symptoms in adults. 32 participants will receive either the drug or a placebo. Researchers will measure symptom severity, brain activity, and eye tracking to see if the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SPG302 (a small synthetic molecule)
What this could lead to: If successful, this could point toward a new treatment option for schizophrenia symptoms.
What could go wrong: This is a small, early-phase trial with only 32 participants. The drug may not improve symptoms or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Box Hill Hospital - Eastern Health

Box Hill, Victoria, 3128, Australia
CenExel CNS

Garden Grove, California, 92845, United States
Multidisciplinary Alfred Psychiatry Research Centre (MAPrc)

Melbourne, Victoria, 3004, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.